Dimension Therapeutics, Inc.l
(NASDAQ GS: DMTX)
Attention investors who purchased shares of Dimension Therapeutics, Inc.l before August 25, 2017:
Rigrodsky & Long is investigating potential claims against the board of directors of Dimension Therapeutics, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by REGENXBIO Inc.
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Dimension Therapeutics, Inc. (“Dimension” or the “Company”) (NASDAQ GS: DMTX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by REGENXBIO Inc. (“REGENXBIO”) (NASDAQ GS: RGNX). Under the terms of the agreement, shareholders of Dimension will receive 0.1573 shares of REGENXBIO for each share of Dimension common stock.
If you own common stock of Dimension and purchased any shares before August 25, 2017, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242, or by e-mail at email@example.com.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities fraud, shareholder corporate, and shareholder derivative litigation on behalf of shareholders in state and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar outcome.